Al-Khawaja I M, Caruana M P, Prince H, Whittington J, Raftery E B
Am J Cardiol. 1986 Nov 26;58(12):17E-20E. doi: 10.1016/0002-9149(86)90592-8.
The antihypertensive efficacy of bevantolol, a selective beta 1-adrenoreceptor antagonist, was evaluated in 17 patients with essential hypertension, using continuous ambulatory intraarterial blood pressure (BP) monitoring. The study compared a twice-daily regimen (titrated dose of 200 to 600 mg/day) with the same amount given in a single daily dose. Within-patient comparisons of mean hourly systolic and diastolic BPs and heart rate showed a highly significant effect with twice-daily therapy (p less than 0.001) for all of the 24 hours. Similar significant results were obtained with a single morning dose. There was no difference between the pattern or extent of BP reduction with the 2 regimens. The decrease in BP after bevantolol persisted during the physiologic tests (rest, tilt, isometric and dynamic exercise). Four patients developed minor side effects with the single morning dose, and only 1 patient with the twice-daily regimen. These effects included tiredness, fatigue and dizziness. Unlike pure beta-blocking agents, bevantolol controlled the early morning increase in BP, lending support to the belief that it possesses vasodilatory properties in addition to beta blockade. These results suggest that bevantolol may be useful as first-line therapy in a once-daily dosage for the treatment of essential hypertension.
使用动态动脉血压监测，对17例原发性高血压患者评估了选择性β1 -肾上腺素能受体拮抗剂倍凡洛尔的降压疗效。该研究比较了每日两次给药方案（滴定剂量为200至600毫克/天）与相同剂量每日一次给药的情况。患者自身每小时平均收缩压、舒张压和心率的比较显示，每日两次治疗在24小时内均有高度显著效果（p < 0.001）。单次晨起给药也获得了类似的显著结果。两种给药方案在血压降低的模式或程度上没有差异。倍凡洛尔给药后血压下降在生理测试（静息、倾斜、等长和动态运动）期间持续存在。4例患者单次晨起给药出现轻微副作用，每日两次给药方案仅有1例患者出现副作用。这些副作用包括疲倦、乏力和头晕。与单纯β受体阻滞剂不同，倍凡洛尔可控制清晨血压升高，这支持了其除β受体阻滞作用外还具有血管舒张特性的观点。这些结果表明，倍凡洛尔每日一次给药作为一线治疗用于原发性高血压可能有效。
